Autolus Therapeutics plc delivers a breakthrough CAR-T therapy for B-ALL with strong safety/efficacy. Learn more about AUTL ...

Mount Gilead Baptist Church stands at the corner of Grove and Fifth streets in downtown Fort Worth. It landed on Historic ...

FRIDAY, June 6, 2025 (HealthDay News) — A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug ...

At Gilead, we’re advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them ...

The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...

Protara, hoping to ultimately transition to a commercial stage company, snagged a chief commercial officer in Bill Conkling, ...

The karaoke scene in the finale of The Handmaid's Tale may have confused some fans, but it actually calls back to a pivotal ...

Gilead Sciences Inc. closed 7.92% below its 52-week high of $119.96, which the company achieved on March 10th.

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” first quarter 2025 ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...